ES2880489T3 - Prueba serológica para el control de terapia de carcinoma VPH16 positivo - Google Patents

Prueba serológica para el control de terapia de carcinoma VPH16 positivo Download PDF

Info

Publication number
ES2880489T3
ES2880489T3 ES17835602T ES17835602T ES2880489T3 ES 2880489 T3 ES2880489 T3 ES 2880489T3 ES 17835602 T ES17835602 T ES 17835602T ES 17835602 T ES17835602 T ES 17835602T ES 2880489 T3 ES2880489 T3 ES 2880489T3
Authority
ES
Spain
Prior art keywords
antibodies
hpv16
antigens
binding
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17835602T
Other languages
English (en)
Spanish (es)
Inventor
Ralf Hilfrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abviris Deutschland GmbH
Original Assignee
Abviris Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abviris Deutschland GmbH filed Critical Abviris Deutschland GmbH
Application granted granted Critical
Publication of ES2880489T3 publication Critical patent/ES2880489T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES17835602T 2016-12-13 2017-12-13 Prueba serológica para el control de terapia de carcinoma VPH16 positivo Active ES2880489T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma

Publications (1)

Publication Number Publication Date
ES2880489T3 true ES2880489T3 (es) 2021-11-24

Family

ID=61027644

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17835602T Active ES2880489T3 (es) 2016-12-13 2017-12-13 Prueba serológica para el control de terapia de carcinoma VPH16 positivo

Country Status (22)

Country Link
US (2) US10852303B2 (https=)
EP (1) EP3384292B1 (https=)
JP (2) JP7329244B2 (https=)
KR (1) KR102433541B1 (https=)
CN (1) CN110073219B (https=)
BR (1) BR112019011681A2 (https=)
CA (1) CA3045729A1 (https=)
CY (1) CY1124297T1 (https=)
DE (1) DE102016124171A1 (https=)
DK (1) DK3384292T3 (https=)
ES (1) ES2880489T3 (https=)
HR (1) HRP20211080T1 (https=)
HU (1) HUE054969T2 (https=)
LT (1) LT3384292T (https=)
PL (1) PL3384292T3 (https=)
PT (1) PT3384292T (https=)
RS (1) RS62135B1 (https=)
RU (1) RU2757629C2 (https=)
SI (1) SI3384292T1 (https=)
SM (1) SMT202100421T1 (https=)
WO (1) WO2018108957A1 (https=)
ZA (1) ZA201804516B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
US7067258B2 (en) * 2002-04-30 2006-06-27 Merck & Co., Inc. Human papillomavirus multiplexed assay
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
DE102010061028A1 (de) * 2010-12-03 2012-06-06 Ralf Hilfrich Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests
DE102011053741A1 (de) * 2011-09-19 2013-03-21 Ralf Hilfrich Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen

Also Published As

Publication number Publication date
SI3384292T1 (sl) 2021-08-31
RU2757629C2 (ru) 2021-10-19
EP3384292B1 (en) 2021-04-21
KR102433541B1 (ko) 2022-08-18
LT3384292T (lt) 2021-07-26
KR20190097155A (ko) 2019-08-20
BR112019011681A2 (pt) 2019-10-15
ZA201804516B (en) 2019-04-24
RS62135B1 (sr) 2021-08-31
CY1124297T1 (el) 2022-07-22
RU2019121882A3 (https=) 2021-04-09
RU2019121882A (ru) 2021-01-15
SMT202100421T1 (it) 2021-09-14
JP2020501162A (ja) 2020-01-16
JP7329244B2 (ja) 2023-08-18
US20190113516A1 (en) 2019-04-18
US11506667B2 (en) 2022-11-22
CN110073219B (zh) 2023-09-05
CN110073219A (zh) 2019-07-30
US20200408768A1 (en) 2020-12-31
EP3384292A1 (en) 2018-10-10
JP2023029377A (ja) 2023-03-03
PL3384292T3 (pl) 2021-10-25
DK3384292T3 (da) 2021-06-28
WO2018108957A1 (en) 2018-06-21
HRP20211080T1 (hr) 2021-10-01
HUE054969T2 (hu) 2021-10-28
CA3045729A1 (en) 2018-06-21
US10852303B2 (en) 2020-12-01
DE102016124171A1 (de) 2018-06-14
PT3384292T (pt) 2021-07-22

Similar Documents

Publication Publication Date Title
De Jong et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
ES2213754T3 (es) Particulas quimericas de tipo papilomavirus.
KR101514473B1 (ko) 다중 유전자 발현용 벡터
Dong et al. Immunodiagnosis and immunotherapeutics based on human papillomavirus for HPV-induced cancers
US20100167269A1 (en) Detection method for human pappilomavirus (HPV) and its application in cervical Cancer
MX2008008453A (es) Adenovirus adipogenicos como biomarcadores para enfermedades.
Xiao et al. Observations on the expression of human papillomavirus major capsid protein in HeLa cells
Zhao et al. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity
US20040171806A1 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
ES2880489T3 (es) Prueba serológica para el control de terapia de carcinoma VPH16 positivo
Heim et al. Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer
Einstein Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines
ES2709331T3 (es) Ensayo inmunológico para la detección de oncoproteínas E7 en muestras biológicas
Matsumoto et al. DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type‐specific antibodies neutralizing pseudovirions constructed in vitro
ES2237204T3 (es) Ensayo de neutralizacion usando particulas similares al virus de papilomavirus humano.
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
Rajsri et al. Exploring the role of HPV-from sexually transmitted infection to oropharyngeal carcinoma
US8715681B2 (en) Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications
Hassen et al. Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women
Rajsri et al. Exploring the role of HPV: from Sexually transmitted infection to Oropharyngeal Cancers
Newton et al. Immune Responses to Human Papillomavirus After Infection and Vaccination
Wang THE ROLE OF E6 PROTEIN IN HUMAN PAPILLOMAVIRUS ASSOCIATED UPPER AIRWAY DISEASES
Demeter et al. Human papillomaviruses
Xu et al. Epitome mapping of E6 and E7 proteins from high-risk oncogenic HPV types 16, 18 and 45
Squarzon Evaluation of HPV type-specific antibody response induced by the prophylactic quadrivalent vaccine